17 January 2023
Intuitive Investments Group plc
("IIG" or the "Company")
Result of Annual General Meeting and Directorate Change
Intuitive Investments Group plc (AIM: IIG), a closed-end investment company focussed on the life sciences sector, announces that at the Annual General Meeting held today, all resolutions were duly passed.
The results of the proxy voting are summarised in the table below:
| Resolution | Votes For | Votes Against | Withheld |
| One | 30,133,533 | 0 | 0 |
| Two | 30,133,533 | 0 | 0 |
| Three | 30,133,533 | 0 | 0 |
| Four | 30,133,533 | 0 | 0 |
| Five | 30,133,533 | 0 | 0 |
| Six | 30,133,533 | 0 | 0 |
| Seven | 30,133,533 | 0 | 0 |
| Eight | 30,133,533 | 0 | 0 |
IIG also announces that Dr Cormac Kilty, Independent Non-Executive Director, has informed the Board of his intention to step down at the end of this month. Given the size of the Company, where the Board, further to Cormac's retirement, will consist of three independent non-executive and one executive director, a replacement is not being sought.
Julian Baines, Chairman of IIG, commented:
"On behalf of everyone at IIG, I would like to thank Cormac for his service at IIG as a non-executive director, particularly his hard work at the time of flotation and his subsequent input into the Company's investments. He will be sorely missed at Board meetings."
For further information, please contact:
| Intuitive Investments Group plc | |
| Julian Baines, Chairman Robert Naylor, CEO | Via Walbrook PR |
|
| |
| SP Angel Corporate Finance LLP - Nominated Adviser | +44 (0) 20 3470 0470 |
| Jeff Keating / David Hignell / Kasia Brzozowska
| |
| Turner Pope Investments (TPI) Ltd - Broker | +44 (0) 20 3657 0050 |
| Andrew Thacker / James Pope | |
|
| |
| Walbrook PR Limited - Media & Investor Relations | +44 (0)20 7933 8780 or intuitive@walbrookpr.com |
| Paul McManus / Sam Allen | +44 (0) 7980 541 893 / +44 (0) 7502 558 258 |
About Intuitive Investments Group plc
Intuitive Investments Group plc is an investment company seeking to provide investors with exposure to a portfolio concentrating on fast growing and/or high potential Life Sciences businesses operating predominantly in the UK, continental Europe and the US, utilising the Board's experience and in particular that of the Chairman of the Investment Committee, David Evans, to seek to generate capital growth over the long term for shareholders
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.